Professor Michael Makris Shares Albert Farrugia’s Commentary on the UK Infected Blood Inquiry
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on LinkedIn:
“A fascinating commentary on the UK Infected Blood Inquiry by Albert Farrugia has been published in the journal Haemophilia. He gives a unique perspective as a person with haemophilia B who was infected with hepatitis B and C through FIX concentrate, but also professionally as a plasma fractionation scientist.
He supports the compensation to affected individuals but questions several of the Inquiry’s key conclusions.
It is difficult to understand why the Inquiry did not call on Albert to give oral evidence; surely there can be few persons alive today with more insight on the matter.
The PDF of the article is freely available”
Title: The Infected Blood Inquiry in the UnitedKingdom—Let the Dust Settle
Correspondence: Albert Farrugia
You can read the full article here.
Find more on Hemostasis Today.
-
Sep 9, 2025, 05:53Noel Hiney Highlights the Value of Blood Donation and Community Support
-
Sep 8, 2025, 22:5650% of DOAC Doses are Inappropriate in Older Adults? On The Role of Appropriate Dosing
-
Sep 8, 2025, 07:48Andreas Zirlik Announces EAS Rare Lipid Disorders Course at 7th Cardio Summit Graz
-
Sep 8, 2025, 07:11Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
-
Sep 8, 2025, 06:54Indraneel Deshmukh Presenting Posters on Polycytemia Vera and More at SOHO 2025
-
Sep 8, 2025, 14:22GLP-1 Receptor Agonists and Cardiovascular Benefits․ Role of Clinical Features
-
Sep 8, 2025, 14:21Hamza A. Salim: CTA Collateral Impairment Score Enhances Stroke Prognosis Accuracy
-
Sep 8, 2025, 06:19Maria Abbattista: From Combined Hormonal Contraceptives to Cerebral Vein Thrombosis
-
Sep 8, 2025, 06:12David Smadja: Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
-
Sep 7, 2025, 17:19Tessa Jaspers and Colleagues on Current Evidence Not Supporting Routine Anti-Xa Monitoring in Use of LMWH
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships
-
Sep 8, 2025, 15:10Michael Makris on WHO’s Essential Medicines List Update: A Win for the Global Haemophilia Community
-
Sep 8, 2025, 14:26European Haemophilia Consortium Marks World PT Day: Physiotherapy Empowers People with Bleeding Disorders
-
Sep 8, 2025, 07:03Omar Adwan Explains the Key Difference Between Serum and Plasma
-
Sep 8, 2025, 07:00French Reference Center for Hemophilia Presented at The 22nd Turkish Hemophilia Congress